• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    4/11/24 4:31:16 PM ET
    $ACOR
    $AKAN
    $AUTL
    $BGXX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • Ontrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million.
    • Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82% to $1.93. The company's market cap stands at $47.8 million.
    • Lyell Immunopharma (NASDAQ:LYEL) stock rose 7.5% to $2.86. The market value of their outstanding shares is at $726.5 million.
    • iSpecimen (NASDAQ:ISPC) shares rose 6.38% to $0.24. The market value of their outstanding shares is at $2.1 million.
    • Akanda (NASDAQ:AKAN) shares moved upwards by 5.89% to $0.16. The company's market cap stands at $1.9 million.
    • Bright Green (NASDAQ:BGXX) shares moved upwards by 5.0% to $0.25. The market value of their outstanding shares is at $46.3 million.

    Losers

    • Motus GI Hldgs (NASDAQ:MOTS) stock declined by 32.6% to $0.28 during Thursday's after-market session. The market value of their outstanding shares is at $1.4 million.
    • Acorda Therapeutics (NASDAQ:ACOR) stock declined by 17.55% to $0.55.
    • Nurix Therapeutics (NASDAQ:NRIX) shares decreased by 9.36% to $15.6. The company's market cap stands at $766.7 million. As per the news, the Q1 earnings report came out yesterday.
    • Biolase (NASDAQ:BIOL) stock declined by 5.9% to $0.14. The company's market cap stands at $4.5 million.
    • Entrada Therapeutics (NASDAQ:TRDA) stock fell 5.59% to $12.52. The market value of their outstanding shares is at $420.6 million.
    • Autolus Therapeutics (NASDAQ:AUTL) stock declined by 5.26% to $5.05. The company's market cap stands at $1.3 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AKAN
    $AUTL
    $BGXX

    CompanyDatePrice TargetRatingAnalyst
    Lyell Immunopharma Inc.
    $LYEL
    3/9/2026$34.00Mkt Outperform
    Citizens
    Autolus Therapeutics plc
    $AUTL
    2/17/2026$9.00Buy
    H.C. Wainwright
    Entrada Therapeutics Inc.
    $TRDA
    2/11/2026$20.00Buy
    Guggenheim
    Entrada Therapeutics Inc.
    $TRDA
    1/28/2026$21.00Outperform
    Oppenheimer
    Nurix Therapeutics Inc.
    $NRIX
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    Lyell Immunopharma Inc.
    $LYEL
    12/9/2025$45.00Neutral → Buy
    H.C. Wainwright
    Nurix Therapeutics Inc.
    $NRIX
    11/24/2025$30.00Buy
    Truist
    Nurix Therapeutics Inc.
    $NRIX
    10/21/2025$24.00Outperform
    Mizuho
    More analyst ratings

    $ACOR
    $AKAN
    $AUTL
    $BGXX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

    AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluationAutolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in ​lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in pro

    3/27/26 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akanda Corp. Driving Recurring Revenue Growth: $2 Million Cash Flow Secured Through Fiber Acquisition

    Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its wholly owned subsidiary, First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, are pleased to announce an expansion of its dark fiber network with the addition of approximately 200 kilometres, increasing total network coverage to approximately 900 kilometres across Central Mexico.This milestone is expected to materially advance FTF's strategy to build a scaled, high-margin, cash-flow-generating digital infrastructure platform in what the Company believes is one of Latin America's most attractive and undersupplied connectivity ma

    3/26/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

    BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that two oral presentations and three poster presentations highlighting the breadth of its research pipeline and scientific leadership will be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting, to be held April 17-22, 2026, in San Diego, California. The presentations will provide additional mechanistic validation of CBL-B, Aurora kinase A (AURKA) and mutant BRAF as therapeutic targets across multiple can

    3/23/26 4:05:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AKAN
    $AUTL
    $BGXX
    SEC Filings

    View All

    SEC Form 10-K filed by Autolus Therapeutics plc

    10-K - Autolus Therapeutics plc (0001730463) (Filer)

    3/27/26 4:39:47 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

    SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    3/27/26 11:09:15 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Autolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Autolus Therapeutics plc (0001730463) (Filer)

    3/27/26 8:02:10 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AKAN
    $AUTL
    $BGXX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Arch Venture Partners Ix, Llc bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/9/26 4:36:20 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Fund Xiii, L.P. bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/9/26 4:34:54 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACOR
    $AKAN
    $AUTL
    $BGXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Richardson Ryan

    3 - Autolus Therapeutics plc (0001730463) (Issuer)

    3/23/26 4:54:04 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Piccina Cintia

    3 - Autolus Therapeutics plc (0001730463) (Issuer)

    3/18/26 8:40:01 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Butitta Cynthia M

    3 - Autolus Therapeutics plc (0001730463) (Issuer)

    3/18/26 8:01:43 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AKAN
    $AUTL
    $BGXX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for RYZUMVI issued to OCUPHIRE PHARMA INC

    Submission status for OCUPHIRE PHARMA INC's drug RYZUMVI (ORIG-1) with active ingredient PHENTOLAMINE has changed to 'Approval' on 09/25/2023. Application Category: NDA, Application Number: 217064, Application Classification: Type 3 - New Dosage Form

    9/26/23 12:02:02 PM ET
    $OCUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AKAN
    $AUTL
    $BGXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens initiated coverage on Lyell Immunopharma with a new price target

    Citizens initiated coverage of Lyell Immunopharma with a rating of Mkt Outperform and set a new price target of $34.00

    3/9/26 9:07:38 AM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Autolus Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $9.00

    2/17/26 8:13:55 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Entrada Therapeutics with a new price target

    Guggenheim initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $20.00

    2/11/26 7:51:55 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AKAN
    $AUTL
    $BGXX
    Leadership Updates

    Live Leadership Updates

    View All

    Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

    Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoingPhase 1 trial is ongoing for LYL273, an enhanced GCC-targeted CAR T-cell candidate for metastatic colorectal cancer; seven new patients treated without dose-limiting toxicity and including dose escalation to Dose Level 3Smital Shah was appointed Chief Financial and Business Officer in March 2026Second $50 million tranche of $100 million equity private placement closed in March 2026 after achievement of clinical milestone for ronde-celCash of approximate

    3/12/26 4:05:00 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

    SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger

    11/10/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entrada Therapeutics Reports Second Quarter 2025 Financial Results

    -- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expected into Q2 2027 with $354 million in cash, cash equivalents and marketable securities as of June 30, 2025 -- BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) to

    8/6/25 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AKAN
    $AUTL
    $BGXX
    Financials

    Live finance-specific insights

    View All

    Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

    AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluationAutolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in ​lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in pro

    3/27/26 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

    LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results and operational highlights before open of U.S. markets on Friday, March 27, 2026. Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN,

    3/16/26 4:10:00 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

    93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L settingManageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxisLyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, Associate Professor at the David Geffen School of Medicine, University of California, Los Angel

    12/7/25 4:30:00 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AKAN
    $AUTL
    $BGXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

    SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    11/14/24 4:32:31 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care